• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Court Approves CCAA Plans to Resolve Tobacco Product-Related Claims and Litigation in Canada

    3/7/25 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email

    Regulatory News:

    Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding has approved a plan of compromise and arrangement for RBH (the Plan). The Plan, as approved, will resolve all tobacco product-related claims and litigation in Canada against RBH and its affiliates, including PMI. The court also approved substantially similar plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM).

    As previously disclosed, RBH's court-appointed mediator and monitor filed a proposed plan for RBH in October 2024. In January 2025, RBH filed an objection to the proposed plan, arguing that the proposed plan could not be approved because the issue of allocation of the CAD 32.5 billion aggregate settlement amount among RBH, ITL, and JTIM remained unresolved. Following a judicial hearing on the proposed plan, RBH, JTIM and ITL reached a consensual resolution of all outstanding objections to the proposed plan filed by the companies, including with respect to the allocation issue, resulting in plan amendments that, among other things, will permit RBH to retain CAD 750 million (approximately USD 525 million) in accumulated cash.

    After years of mediation to resolve long-pending tobacco product-related litigation in Canada, PMI is pleased that this legal process will now draw to a close, allowing RBH and its stakeholders to focus on the future.

    Select Terms of Plan as Approved by Court

    • Under the resolution contemplated by the Plan, RBH, ITL and JTIM will pay an aggregate global settlement amount of CAD 32.5 billion (approximately USD 22.7 billion). This amount will be funded by an upfront payment equal to the companies' cash and cash equivalents on hand plus court deposits, less the CAD 750 million that RBH will be permitted to retain (RBH Retained Amount), and annual payments based on a percentage of the companies' aggregate "net after-tax income" (NATI, as defined in the Plan and excluding that generated by alternative products such as heat-not-burn, nicotine pouches, and e-vapor) until the global settlement amount is paid in full;1
    • RBH will be free to deal in its sole discretion with the RBH Retained Amount of CAD 750 million, including being free to transfer or distribute such monies outside of Canada;
    • RBH and its affiliates, including PMI and its indemnitees, will obtain a release of claims relating to the manufacture, marketing, sale, or use of or exposure to, RBH's combustible and traditional smokeless tobacco products based on conduct prior to the effective date of the Plan; related litigation would also be dismissed;
    • Alternative product businesses (including heat-not-burn, e-vapor, and nicotine pouches) will be maintained separately from RBH's combustible business; and
    • The Plan also contains a number of operating covenants that would govern RBH's combustible business going forward until the settlement amount has been paid.

    Implementation of the Plan is subject to certain conditions precedent, including exhaustion of appeal rights and execution and delivery of definitive documentation, such as execution of contractual releases. Subject to satisfaction of the conditions precedent, it is expected that the Plan will be implemented and become effective in 2025. The payment of any dividends by RBH derived from NATI after implementation of the Plan is expected to be incremental to PMI's operating cash flow and adjusted diluted EPS. Following implementation of the Plan under the terms approved by the Court, we expect that RBH will remain deconsolidated under U.S. GAAP.

    Forward-Looking & Cautionary Statements

    This press release contains projections of future results and goals and other forward-looking statements, including statements regarding expected financial or operational performance; capital allocation plans; business plans and strategies; the likelihood and impact of the Plan; and the likelihood of RBH remaining deconsolidated. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.

    PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco and/or nicotine use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; the impact of natural disasters and pandemics on PMI's business; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to introduce, commercialize, and grow smoke-free products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our smoke-free products performance.

    PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2024. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.

    Philip Morris International: Delivering a Smoke-Free Future

    Philip Morris International is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested over $14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies' IQOS and ZYN brands. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. As of December 31, 2024, PMI's smoke-free products were available for sale in 95 markets, and PMI estimates that 38.6 million adults around the world use PMI's smoke-free products. The smoke-free business accounted for approximately 39% of PMI's total full-year 2024 net revenues. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences. References to "PMI", "we", "our" and "us" mean Philip Morris International Inc., and its subsidiaries. For more information, please visit www.pmi.com and www.pmiscience.com.

    __________________________

    1 Annual contributions start at 85% of NATI, with a five-percentage point reduction in NATI every five years until reaching 70%. Annual contributions are contingent on positive NATI of the companies. Such payments and obligations concern only the Canadian affiliates and not the ultimate parent company PMI.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250307667404/en/

    Philip Morris International

    Investor Relations:

    Stamford, CT: +1 (203) 905 2413

    Lausanne: +41 582 424 666

    Email: [email protected]

    Media: David Fraser

    Lausanne: +41 582 424 500

    Email: [email protected]

    Get the next $PM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    1/23/2024$105.00 → $86.50Buy → Sell
    UBS
    11/16/2023$95.00Neutral
    Redburn Atlantic
    6/20/2023$109.00 → $117.00Neutral → Buy
    Citigroup
    More analyst ratings

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Philip Morris International upgraded by UBS with a new price target

      UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00

      4/25/25 8:25:28 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by Argus

      Argus upgraded Philip Morris International from Hold to Buy

      3/14/25 7:44:58 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Morgan Stanley initiated coverage on Philip Morris International with a new price target

      Morgan Stanley initiated coverage of Philip Morris International with a rating of Overweight and set a new price target of $140.00

      1/16/25 7:52:12 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres. Smoke-Free Oral Products Dahlgren Lars sold $562,740 worth of shares (3,679 units at $152.96), decreasing direct ownership by 12% to 26,828 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      3/7/25 1:51:03 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • President, Europe Region Andolina Massimo sold $2,730,875 worth of shares (17,500 units at $156.05), decreasing direct ownership by 17% to 86,737 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      2/25/25 10:49:41 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • President, Europe Region Andolina Massimo covered exercise/tax liability with 823 shares, decreasing direct ownership by 0.78% to 104,237 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      2/21/25 12:03:21 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    SEC Filings

    See more

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      5/7/25 9:50:34 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      4/30/25 4:29:49 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form FWP filed by Philip Morris International Inc

      FWP - Philip Morris International Inc. (0001413329) (Subject)

      4/30/25 12:57:07 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Holds 2025 Virtual Annual Meeting of Shareholders

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) held its 2025 Annual Meeting of Shareholders today. André Calantzopoulos, Chairman of the Board, addressed shareholders and answered questions. Jacek Olczak, Chief Executive Officer, gave a business presentation, which included an overview of PMI's: excellent 2024 performance and impressive start to 2025; achievement of several key milestones in its smoke-free journey; positive results in the execution of its multicategory strategy; ability to deliver sustainable growth and returns in 2025 and beyond; steadfast commitment to shareholder returns. "Our smoke-free transformation continues to advance rapidly. We mark

      5/7/25 9:44:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International to Host Webcast of 2025 Virtual Annual Meeting of Shareholders

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast of its 2025 Annual Meeting of Shareholders on Wednesday, May 7, 2025, at 9:00 a.m. ET. The meeting will be in a virtual format and can be accessed at www.virtualshareholdermeeting.com/PM2025. Presentation slides, script and an archived recording of the webcast will be available at the same link. The recording will be available for one year from the date of the meeting. During the meeting, André Calantzopoulos, Chairman of the Board, and Jacek Olczak, Chief Executive Officer, will address shareholders and answer questions. Only shareholders of record with a valid 16-digit control number will be

      4/30/25 9:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International CEO Jacek Olczak Addresses Emerging Global Divide in Regulatory Approaches to Consumer Innovation

      Olczak issues call for pragmatic policies that accelerate advances in public health, noting that approximately 20% of smokers globally lack access to better alternatives to cigarettes Jacek Olczak, Chief Executive Officer of Philip Morris International Inc. (NYSE:PM), outlined the need for common-sense regulations in the consumer goods sector while addressing global leaders at Semafor's annual World Economy Summit in Washington, D.C., on April 25, 2025. Olczak emphasized the sector's potential for innovation-led growth despite the volatile economic environment. He stressed, however, that without appropriate regulation and policy frameworks to enable scientific evaluation and consumer acces

      4/28/25 8:15:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:21:26 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:05:54 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      1/29/24 3:26:29 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    See more
    • Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

      Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

      9/17/24 9:11:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Names New External Affairs Leader

      Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

      3/26/24 5:48:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

      In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

      3/4/24 6:48:00 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Financials

    Live finance-specific insights

    See more
    • Philip Morris International Reports First-Quarter 2025 Results and Raises 2025 Full-Year Adjusted Diluted EPS Forecast for Currency Only

      Reported Diluted EPS Grew 24.6% to $1.72 Adjusted Diluted EPS Grew 12.7% to $1.69; and by 17.3% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 first-quarter results.1 "We achieved exceptionally strong performance in the first quarter, with continued volume growth supporting an excellent top-line performance and very strong margin expansion," said Jacek Olczak, Chief Executive Officer. "Our smoke-free business goes from strength to strength, delivering organic growth of over 20% in net revenues and over 33% in gross profit." "We remain confident in our ability to deliver superior results, despite an uncertain and volatile glob

      4/23/25 6:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Court Approves CCAA Plans to Resolve Tobacco Product-Related Claims and Litigation in Canada

      Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding has approved a plan of compromise and arrangement for RBH (the Plan). The Plan, as approved, will resolve all tobacco product-related claims and litigation in Canada against RBH and its affiliates, including PMI. The court also approved substantially similar plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM). As previously disclosed, RBH's court-appointed mediator and monitor filed a pr

      3/7/25 8:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Declares Regular Quarterly Dividend of $1.35 Per Share

      Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on April 10, 2025, to shareholders of record as of March 20, 2025. The ex-dividend date is March 20, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consist

      3/6/25 10:44:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care